Posted by Michael Wonder on 28 Sep 2022
Dupixent (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
28 September 2022 - Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials.
Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
